Duvelisib has marked response, survival benefi... - CLL Support

CLL Support

23,089 members39,652 posts

Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma

Cllcanada profile image
CllcanadaTop Poster CURE Hero
1 Reply

"The way we treat patients with CLL is changing rapidly as we move from standard chemotherapy-based approaches to more targeted therapies," said principal investigator Ian W. Flinn, MD, Ph.D., Director of the Lymphoma Research Program at Sarah Cannon Research Institute in Nashville. "Based on these data, duvelisib may offer a new treatment option for patients who otherwise may have limited options."

In sub-group analyses, researchers found duvelisib worked just as well as ofatumumab among the hardest-to-treat cases, including those patients with p17 deletion or p53 abnormalities, who have few available therapeutic options. Patients with these genetic mutations who took duvelisib had a 60 percent reduction in their risk of cancer progression or death compared to similar patients in the ofatumumab group.

"These are patients in whom traditional chemotherapy doesn't work," said Dr. Flinn.

More on this new FDA approved for third line treatment 📌

medicalxpress.com/news/2018...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Ironj profile image
Ironj

That’s fantastic news.

Not what you're looking for?

You may also like...

FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018

FDA Approves Duvelisib for CLL and Follicular Lymphoma Published: Monday, Sep 24, 2018 The FDA has...

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce...

Response and Survival Rates for FCR and Ibrutinib

Those of you who waded through my post yesterday on clonal evolution will be glad to know this is a...

CLLSA and Leukaemia Care Joint Response to NHS England regarding Ibrutinib Prescribing as per NICE TA

This is the letter sent to Professor Peter Clarke on 2nd July 2018 for the review of Ibrutinib...

Deciding on CLL Therapy and When to Treat- ONCLive Video discussion Drs. Wierda, Lamanna, Ma, Davids, Coutre

This has been discussed often- when to start treatment. There are many exceptions and special...